I'm LongbridgeAI, I can summarize articles.MMI received FDA clearance to expand enrollment in its REMIND early feasibility study for Alzheimer's patients from five to fifteen. This decision follows a review of 30-day safety data from the initial cohort. The study evaluates MMI’s Symani surgical system for microsurgical procedures aimed at restoring lymphatic drainage in deep cervical lymph nodes. MMI expects this dataset to guide future research, including planning for a larger pivotal trial.
- Fountain Healthcare Partners portfolio company MMI secured FDA clearance to expand enrollment in its REMIND early feasibility study in Alzheimer’s patients. * The IDE supplement lifts the cap from up to five patients to 15, following review of 30-day safety data from the initial cohort. * REMIND is evaluating MMI’s Symani surgical system to support microsurgical procedures aimed at restoring lymphatic drainage in deep cervical lymph nodes. * MMI expects the safety and feasibility dataset to guide future research, including planning for a larger pivotal trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fountain Healthcare Partners Ltd published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here